New Hope for Depression: Pittsburgh Clinics Add Advanced Treatments

PITTSBURGH, PA – February 18, 2026 – For the significant portion of individuals battling depression who find little relief from traditional medications, the path to wellness can feel frustratingly out of reach. Now, new hope is arriving in the Pittsburgh area as New Directions Mental Health, a clinic with deep roots in the community, expands its services to include two of the most advanced, life-saving treatments for severe and treatment-resistant depression.

The group announced that its Bloomfield office is now a certified provider of Spravato® (esketamine), a rapid-acting nasal spray, while its Fox Chapel location has introduced NeuroStar Transcranial Magnetic Stimulation (TMS), a non-invasive, drug-free therapy. This expansion marks a significant step in making cutting-edge interventional psychiatry more accessible across Southwestern Pennsylvania.

A New Frontier in Brain Chemistry

For patients with treatment-resistant depression (TRD)—a condition defined by a lack of response to at least two different antidepressant medications—Spravato represents a paradigm shift. Unlike traditional antidepressants that primarily target monoamine neurotransmitters like serotonin and norepinephrine, Spravato works on a different pathway. As the S-enantiomer of ketamine, it is an antagonist of the NMDA receptor, a key player in the brain's glutamate system. This action is believed to trigger a cascade of events that rapidly restores synaptic connections in brain regions impacted by depression.

The most remarkable feature of Spravato is its speed. While conventional antidepressants can take weeks or months to show effects, patients on Spravato have reported significant symptom reduction within hours or days. This rapid onset is particularly critical for those experiencing severe depressive episodes or acute suicidal ideation.

First approved by the FDA in 2019 for TRD in conjunction with an oral antidepressant, Spravato’s application has continued to evolve. In a landmark decision in January 2025, the FDA expanded its approval to allow Spravato as a standalone treatment for Major Depressive Disorder (MDD), further solidifying its role in modern psychiatry. However, its power comes with necessary precautions. Due to risks of sedation, dissociation, and potential for misuse, the treatment is only available through a restricted FDA program called REMS (Risk Evaluation and Mitigation Strategy). Patients must self-administer the nasal spray under the supervision of a healthcare provider at a certified clinic, like the New Directions Bloomfield office, and be monitored for at least two hours after each session.

Harnessing Magnetism for Mood Regulation

In Fox Chapel, New Directions is offering a different but equally innovative approach: NeuroStar Transcranial Magnetic Stimulation (TMS). This FDA-cleared therapy provides a powerful alternative for patients seeking a non-drug treatment or for those who cannot tolerate the side effects of medication, such as weight gain, sexual dysfunction, or cognitive fog.

During a TMS session, a specialized magnetic coil is precisely positioned over the patient's scalp. It delivers focused, repetitive magnetic pulses to the left prefrontal cortex—an area of the brain known to be underactive in individuals with depression. These magnetic fields induce small electrical currents that stimulate dormant neurons, effectively “re-awakening” the brain's mood-regulating circuits. The treatment is non-invasive and requires no anesthesia.

NeuroStar is the first TMS system to receive FDA clearance and is backed by the largest body of clinical data in the field. Studies have shown it to be highly effective, with one head-to-head trial demonstrating that patients were 5.5 times more likely to achieve remission with TMS compared to another trial of a new antidepressant medication. The therapy is typically administered in daily sessions lasting under 20 minutes over several weeks. Crucially, because it is not a systemic drug, the most common side effects are mild and localized, such as temporary scalp discomfort or a mild headache, which typically subside early in the treatment course.

Addressing a Critical Need in Southwestern Pennsylvania

The timing of this expansion is particularly poignant. As a region with long, often overcast winters, Southwestern Pennsylvania sees a predictable rise in depressive symptoms during the colder months, a phenomenon linked to Seasonal Affective Disorder (SAD).

"Mental health is so critical, and typically if someone suffers from depression, we see those symptoms worsen during the winter months," said Dr. Allison Bashe, Regional Clinic Director for New Directions Mental Health. "That is why the timing is perfect for both Bloomfield and Fox Chapel to offer these services and increase the availability of mental health resources to a wider range of those suffering in our community."

The need is substantial. National data suggests that nearly a third of all adults with major depression do not respond to initial treatments, placing them in the treatment-resistant category. By bringing Spravato and TMS to more accessible neighborhood clinics, New Directions is directly addressing this significant unmet need. While major hospital systems like UPMC and AHN also offer these advanced therapies, the expansion by a community-focused provider with a 45-year history in the region broadens the network of care.

Bridging the Gap Between Innovation and Access

While the clinical promise of Spravato and TMS is clear, a critical question for patients is always access. The high cost and complex nature of these therapies have historically been significant barriers. New Directions is aiming to tackle this challenge head-on.

Both Spravato and TMS are now covered by most major insurance plans, but the path to approval is often rigorous. Insurers typically require prior authorization, which involves extensive documentation from the provider confirming a diagnosis of TRD or another qualifying condition, including proof of multiple failed medication trials. This administrative hurdle can delay care and create stress for patients and providers alike.

This is where New Directions' commitment to accessibility becomes vital. The organization accepts most major insurance plans, and notably, many of its locations accept Medicaid and Medicare. This is a crucial differentiator, as it opens the door to state-of-the-art care for populations that are often shut out due to financial constraints. By navigating the complexities of insurance on behalf of their patients, the clinic helps ensure that these treatments are not just for the privileged.

"Our message is that access to quality mental health care is a right, not a privilege and our team of professionals is dedicated to connecting clients to care in a way that works for their individual needs," Dr. Bashe added. By combining in-person services with telehealth options, the organization reinforces its commitment to meeting patients where they are, both geographically and in their journey toward recovery. By integrating these advanced, evidence-based therapies into its comprehensive care model, the long-standing institution is charting a new course for mental wellness in Southwestern Pennsylvania.